Tarceva Could Lock Down Market For First-Line Non-Small Cell Lung Cancer With EGFR Mutation
This article was originally published in The Pink Sheet Daily
Executive Summary
After positive EURTAC study, Genentech and OSI plan to talk to FDA about narrow first-line lung cancer indication and a companion diagnostic.
You may also be interested in...
Astellas Files Personalized Tarceva In First-line Lung Cancer With FDA
If successful, filing in EGFR-positive patients could give Roche/Astellas’ Tarceva a commercial boost, broadening erlotinib’s role in non-small-cell lung cancer.
Astellas Files Personalized Tarceva In First-line Lung Cancer With FDA
If successful, filing in EGFR-positive patients could give Roche/Astellas’ Tarceva a commercial boost, broadening erlotinib’s role in non-small-cell lung cancer.
NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges
Biomarker-guided targeted therapy has become a standard approach to oncology R&D, but few new targeted drugs have reached the market for lung cancer. A new wave of research could change that, and improve the outlook for lung cancer treatment.